ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2019
[Durvalumab after chemoradiotherapy is currently the most promising treatment for stage III NSCLC].
Martin WilhelmPubMed ↗Publisher ↗
No numbers read from the abstract.